Sign in

Colorectal cancer: trials that stopped early

Trials on Colorectal cancer that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.

Stopped early

254 stopped trials give a reason in the registry, latest registry update first. 4 more give no reason and are not listed.

  1. Terminated

    Cryptosporidium Infection and Human Colorectal Cancer

    Reason given in the registry

    “No other patients could be included within the time frame.”

    Quoted unchanged from ClinicalTrials.gov; record updated 6 Nov 2026.

    Ended
    Jun 2025
    Run by
    Lille Catholic University
    Registry record
    NCT04332705
  2. Terminated

    CT-95 in Advanced Cancers Associated With Mesothelin Expression

    Reason given in the registry

    “The study was halted prematurely and will not resume; participants are no longer receiving intervention or undergoing evaluations. The termination was not due to any safety or efficacy concerns.”

    Quoted unchanged from ClinicalTrials.gov; record updated 5 Nov 2026.

    Ended
    Oct 2026
    Phase
    Phase 1
    Run by
    Context Therapeutics Inc.
    Registry record
    NCT06756035
  3. Withdrawn

    ctDNA and Organ Preservation/Pathologic CR in Rectal Cancer

    Reason given in the registry

    “Funding issues”

    Quoted unchanged from ClinicalTrials.gov; record updated 4 Nov 2026.

    Run by
    Massachusetts General Hospital
    Registry record
    NCT05629442
  4. Terminated

    KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer

    Reason given in the registry

    “The study was stopped early due to lack of efficacy.”

    Quoted unchanged from ClinicalTrials.gov; record updated 3 Nov 2026.

    Ended
    Sept 2026
    Phase
    Phase 2
    Run by
    Peking University Cancer Hospital & Institute
    Registry record
    NCT05985109
  5. Suspended

    Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer

    Reason given in the registry

    “PI Request”

    Quoted unchanged from ClinicalTrials.gov; record updated 2 Nov 2026.

    Phase
    Phase 2
    Run by
    M.D. Anderson Cancer Center
    Registry record
    NCT07011550
  6. Suspended

    A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma

    Reason given in the registry

    “Protocol is with FDA review, waiting for funding to be released”

    Quoted unchanged from ClinicalTrials.gov; record updated 28 Oct 2026.

    Phase
    Phase 2
    Run by
    Thomas Jefferson University
    Registry record
    NCT04111172
  7. Terminated

    Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

    Reason given in the registry

    “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will have access to treatment outside of this trial.”

    Quoted unchanged from ClinicalTrials.gov; record updated 26 Oct 2026.

    Ended
    Oct 2026
    Phase
    Phase 1/2
    Run by
    Merus B.V.
    Registry record
    NCT04868877
  8. Terminated

    A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors

    Reason given in the registry

    “Company's strategic decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 23 Oct 2026.

    Ended
    Jun 2026
    Phase
    Phase 1
    Run by
    Astellas Pharma Inc
    Registry record
    NCT06364696
  9. Terminated

    The Impact of Laparotomy and Analgesia Methods on Diaphragm

    Reason given in the registry

    “The study was terminated prematurely because the planned sample size could not be achieved due to insufficient participant recruitment.”

    Quoted unchanged from ClinicalTrials.gov; record updated 22 Oct 2026.

    Ended
    Sept 2025
    Run by
    Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
    Registry record
    NCT06403540
  10. Suspended

    EXtended CriteriA Treatment for LIver Metastases and Heavy Tumour BURden

    Reason given in the registry

    “Not enough patients”

    Quoted unchanged from ClinicalTrials.gov; record updated 22 Oct 2026.

    Phase
    Phase 2
    Run by
    Oslo University Hospital
    Registry record
    NCT04840186
  11. Terminated

    HAI-Floxuridine, or Liver-Tx, Combined With 2nd Line Chemotherapy Versus 2nd Line Chemotherapy Alone for Patients With Colorectal Liver Metastases and Heavy Tumour Burden.

    Reason given in the registry

    “Following temporary halt of inclusion in September 2024, several measures were taken, as previuosly reported. As numbers included by September 2024 were sufficient to conclude for primary endpont, we have decided not to restart the trial.”

    Quoted unchanged from ClinicalTrials.gov; record updated 22 Oct 2026.

    Ended
    Aug 2026
    Phase
    Phase 2
    Run by
    Oslo University Hospital
    Registry record
    NCT04898504
  12. Suspended

    Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca

    Reason given in the registry

    “Pending amendment approval”

    Quoted unchanged from ClinicalTrials.gov; record updated 21 Oct 2026.

    Phase
    Phase 1/2
    Run by
    Virginia Commonwealth University
    Registry record
    NCT03919292
  13. Terminated

    Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

    Reason given in the registry

    “Business reasons and not based on any safety concerns.”

    Quoted unchanged from ClinicalTrials.gov; record updated 21 Oct 2026.

    Ended
    Sept 2026
    Phase
    Phase 1/2
    Run by
    Novartis Pharmaceuticals
    Registry record
    NCT05358249
  14. Terminated

    EO4010 in Previously Treated Metastatic Colorectal Carcinoma

    Reason given in the registry

    “Sponsor decision to stop recruitment in context of overall EO4010 development goals. Stop of recruitment was not related to any safety concern, with the safety profile of EO4010 being benign”

    Quoted unchanged from ClinicalTrials.gov; record updated 19 Oct 2026.

    Ended
    May 2025
    Phase
    Phase 1/2
    Run by
    Enterome
    Registry record
    NCT05589597
  15. Terminated

    A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6

    Reason given in the registry

    “Sponsor decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 14 Oct 2026.

    Ended
    Feb 2026
    Phase
    Phase 1
    Run by
    Boehringer Ingelheim
    Registry record
    NCT06091930
  16. Withdrawn

    Enhancing the Anabolic Effect of Perioperative Nutrition With Insulin While Maintaining Normoglycemia

    Reason given in the registry

    “organisational problems”

    Quoted unchanged from ClinicalTrials.gov; record updated 8 Oct 2026.

    Ended
    Apr 2024
    Phase
    Phase 4
    Run by
    McGill University Health Centre/Research Institute of the McGill University Health Centre
    Registry record
    NCT02032953
  17. Withdrawn

    Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer

    Reason given in the registry

    “Study withdrawn before enrollment of any participant due to a corporate strategic decision. Not related to safety or efficacy concerns.”

    Quoted unchanged from ClinicalTrials.gov; record updated 5 Oct 2026.

    Phase
    Phase 3
    Run by
    Biotech Pharmaceutical Co., Ltd.
    Registry record
    NCT06343116
  18. Suspended

    Trial of ProAgio in Advanced/Metastatic Colorectal Cancer

    Reason given in the registry

    “temporary suspended”

    Quoted unchanged from ClinicalTrials.gov; record updated 2 Oct 2026.

    Phase
    Phase 1
    Run by
    University of Alabama at Birmingham
    Registry record
    NCT06867822
  19. Suspended

    RCT of Mobile Apps & FitBit v. Usual Care

    Reason given in the registry

    “Study is paused for interim analysis.”

    Quoted unchanged from ClinicalTrials.gov; record updated 28 Sept 2026.

    Run by
    Weill Medical College of Cornell University
    Registry record
    NCT03623464
  20. Terminated

    Comparison of Contrast Agents in Liver Magnetic Resonance (MR) for the Detection of Hepatic Metastases

    Reason given in the registry

    “Low Accrual”

    Quoted unchanged from ClinicalTrials.gov; record updated 25 Sept 2026.

    Ended
    May 2025
    Phase
    Phase 4
    Run by
    University of Colorado, Denver
    Registry record
    NCT04973007
  21. Terminated

    A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer

    Reason given in the registry

    “Sponsor decision based on limited anti-cancer activity of TAK-186.”

    Quoted unchanged from ClinicalTrials.gov; record updated 24 Sept 2026.

    Ended
    Jun 2025
    Phase
    Phase 1/2
    Run by
    Takeda
    Registry record
    NCT04844073
  22. Suspended

    A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

    Reason given in the registry

    “Administrative”

    Quoted unchanged from ClinicalTrials.gov; record updated 21 Sept 2026.

    Run by
    ProgenaBiome
    Registry record
    NCT04031469
  23. Suspended

    CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Metastatic Colorectal Cancer

    Reason given in the registry

    “Strategy under discussion”

    Quoted unchanged from ClinicalTrials.gov; record updated 18 Sept 2026.

    Phase
    Phase 2
    Run by
    Holy Stone Healthcare Co., Ltd
    Registry record
    NCT06039202
  24. Suspended

    ARGONAUT: Stool and Blood Sample Bank for Cancer Patients

    Reason given in the registry

    “Currently no funding to continue study.”

    Quoted unchanged from ClinicalTrials.gov; record updated 18 Sept 2026.

    Run by
    Persephone Biosciences
    Registry record
    NCT04638751
  25. Withdrawn

    Phase 2 Trial Of S-531011 With RadScopal In Previously Treated Metastatic Colorectal Cancer

    Reason given in the registry

    “0 participants”

    Quoted unchanged from ClinicalTrials.gov; record updated 11 Sept 2026.

    Ended
    Sept 2026
    Phase
    Phase 2
    Run by
    M.D. Anderson Cancer Center
    Registry record
    NCT07720115
  26. Terminated

    A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation

    Reason given in the registry

    “This was a strategic business decision. There were no safety concerns contributing to this decision.”

    Quoted unchanged from ClinicalTrials.gov; record updated 8 Sept 2026.

    Ended
    Jul 2025
    Phase
    Phase 1
    Run by
    Incyte Corporation
    Registry record
    NCT06039384
  27. Terminated

    Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer

    Reason given in the registry

    “Accrual was terminated due to safety concerns”

    Quoted unchanged from ClinicalTrials.gov; record updated 3 Sept 2026.

    Ended
    Oct 2024
    Phase
    Phase 2
    Run by
    University of Colorado, Denver
    Registry record
    NCT05167409
  28. Terminated

    Evaluating the Effects of an Exercise Intervention on the Gut Microbiota in Stage II-III Colorectal Cancer Survivors

    Reason given in the registry

    “Terminated due to low accrual.”

    Quoted unchanged from ClinicalTrials.gov; record updated 2 Sept 2026.

    Ended
    Jun 2026
    Run by
    Fred Hutchinson Cancer Center
    Registry record
    NCT05930496
  29. Withdrawn

    IX001 TCR-T In the Treatment of Advanced Pancreatic Cancer and Colorectal Cancer Induced by KRAS Mutations

    Reason given in the registry

    “Study was stopped Sponsor discretion. No patients were dosed.”

    Quoted unchanged from ClinicalTrials.gov; record updated 2 Sept 2026.

    Phase
    Phase 1
    Run by
    Shanghai Pudong Hospital
    Registry record
    NCT06487377
  30. Withdrawn

    xDRIVE in Metastatic Colorectal Cancer

    Reason given in the registry

    “Unable to finalize study agreements”

    Quoted unchanged from ClinicalTrials.gov; record updated 2 Sept 2026.

    Run by
    First Ascent Biomedical Inc.
    Registry record
    NCT06929338

Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.